Page 105 - 南京医科大学自然版
P. 105

第45卷第7期       李天时,朱 轶,张忠满,等. 革兰阴性杆菌血流感染的脓毒症相关性脑病患者临床特征分析[J].
                  2025年7月                  南京医科大学学报(自然科学版),2025,45(7):1001-1006,1034                    ·1003 ·


                                       -
                                      G bacillus bloodstream infection
                                        in adult patients with sepsis
                                             (n=336)              129 patients were excluded:
                                                                  ① Central nervous system infection(n=12)
                                                                  ② Acute hepatic or renal failure(n=29)
                                           Included patients      ③ Poisoning(n=5)
                                             (n=207)              ④ Previous neurological deficits(n=59)
                                                                  ⑤ The data are severely missing(n=24)
                                   SAE group        non⁃SAE group
                                    (n=92)            (n=115)
                                                      图1   研究人群纳排流程
                                    Figure 1 Flowchart of study population inclusion and exclusion process

                                              表1 SAE组与无SAE组患者的基线特征分析
                               Table 1 Baseline characteristics analysis of patients in the SAE and non⁃SAE group
                          Variable              Total(n=207)       SAE(n=92)         non⁃SAE(n=115)         P
                 Age[years,M(P25,P75 )]          66(55,75)         66(53,74)           66(55,75)          0.702
                 Male[n(%)]                      125(60.4)          62(67.4)            63(54.8)          0.065
                 BMI[kg/m ,M(P25,P75 )]        23.2(21,25.4)     24.1(21.3,26.0)      23(20.8,25.2)       0.130
                         2
                 Bacillus[n(%)]                                                                           0.126
                   Escherichia coli              73(37.7)           27(29.3)            45(40.0)
                   Klebsiella pneumoniae         71(30.9)           31(33.7)            40(34.8)
                   ESBLs                         48(23.7)           27(29.3)            21(18.3)
                   CRE                           13(5.8)             7(7.6)              6(5.2)
                   Others                         2(1.9)             0(0)                2(1.7)
                 Primary infection[n(%)]                                                                  0.004
                   Urinary system                55(26.5)           22(23.9)            33(28.7)
                   Digestive system              84(40.5)           29(31.5)            55(47.8)
                   Respiratory system             11(5.3)            9(9.8)              2(1.7)
                   Other                         26(12.5)           17(18.5)             9(7.8)
                   Undetermined                  31(14.9)           15(16.3)            16(13.9)
                 Co⁃morbidity[n(%)]
                   Hypertension                  99(47.8)           47(51.1)            52(45.2)          0.401
                   DM                            87(42.0)           48(52.2)            39(33.9)          0.008
                   Stroke                        32(15.4)           19(20.7)            13(11.3)          0.065
                   CHD                           30(14.4)           15(16.3)            15(13.0)          0.508
                   Tumour                        47(22.7)           21(22.8)            26(22.6)          0.970
                   Immunosuppressants            36(17.3)           13(14.1)            23(20.0)          0.268
                   Catheterization               50(24.1)           30(32.6)            20(17.4)          0.011
                   Chronic renal disease          6(2.8)             3(3.3)              3(2.6)           0.548
                   Chronic hepatic disease       13(6.2)             6(6.5)              7(6.1)           0.898
                 SOFA score[M(P25,P75 )]          6(3,10)           10(6,13)            4(2,6)           <0.001
                 PBS score[M(P25,P75 )]           2(0,4)             5(3,8)             2(1,2)           <0.001
                 Life support therapy[n(%)]

                   MV                            48(23.1)           45(48.9)             3(2.6)          <0.001
                   CRRT                          30(14.4)           26(28.3)             4(3.5)          <0.001
                   Vasoactive agent              68(32.8)           50(54.3)            18(15.7)         <0.001
                 30⁃day survival rate[n(%)]      176(85.0)          64(69.6)           112(97.4)         <0.001
                   SAE:sepsis associated encephalopathy;BMI:body mass index;ESBLs:extended spectrum beta⁃lactamases;CRE:carbapenem⁃resistant enterobac⁃
                teriaceae;DM:diabetes mellitus;CHD:coronary heart disease;SOFA score:sepsis⁃related organ failure assessment score;PBS score:the Pitt bacteremia
                score;MV:mechanical ventilation;CRRT:continuous renal replacement therapy.
   100   101   102   103   104   105   106   107   108   109   110